Infection-related mortality (IRM) is responsible for a major proportion of all cases of non-relapse mortality (NRM) after allogeneic PBSCT (alloPBSCT). We analyzed 580 consecutive adults who received a first alloPBSCT from an HLA-identical sibling from 1994 to 2008 at a single institution to describe the severe infections and report the incidence, causes and risk factors for IRM and NRM. Both IRM and NRM decreased with time; within the period of 1994-2000, the 2-year incidence of IRM and NRM was 22 and 31%, respectively, vs 11 and 16% within the period of 2001-2008 (Po0.05 for both comparisons). In multivariate analysis, the variables that increased IRM were within the earlier period of 1994-2000 (Po0.01), poor performance status (Po0.01), grade II-IV acute GVHD (Po0.001) and invasive fungal infection (IFI) (Po0.001) or CMV disease (Po0.001) after transplant. With respect to NRM, earlier time period was also identified as a risk factor (Po0.001), as well as IFIs (Po0.001) and CMV disease (Po0.001). The intensity of the conditioning regimen had no effect on IRM and NRM. These results showed a significant reduction in IRM and NRM over a period of 15 years. The development of IFIs and CMV disease continue to have an impact on NRM.
Introduction
Opportunistic infections are a major identifiable cause of non-relapse mortality (NRM) in recipients of allogeneic hematopoietic SCT (alloHSCT). The major pathogens involved vary during the post transplant period, and the risk of suffering each type of infection is also influenced by patient characteristics, type of alloHSCT, onset and duration of GVHD, availability of efficient diagnostic methods and type of anti-infectious prophylaxis and treatment. 1 The practice of alloHSCT is in continuous evolution, especially with respect to patient selection, conditioning regimens, donor types and histocompatibility matching techniques, stem cell sources and their ex vivo manipulation and GVHD prophylaxis. All these aspects may influence NRM and, specifically, infection-related mortality (IRM). Center-specific differences in the incidence of NRM and IRM may also exist, being extremely difficult to identify the reasons for this heterogeneity. 2 Post-alloHSCT management and supportive care also change over time, with the aim of reducing regimen-related toxicity, NRM and the incidence of mortality from life-threatening bacterial, viral, fungal and parasitic opportunistic infections. 3 The impact of these changes on the incidence of severe infections after an alloHSCT, IRM and overall NRM has not been extensively studied. In addition, the risk of dying from each specific type of infection may also vary over time, presumably due to the improvement in the methods for their early diagnosis and the availability of more effective treatments with lower toxicity.
To avoid confounding factors, such as stem cell source, donor type, level of histocompatibility matching and center effect, this study includes only adult recipients of a first alloHSCT from an HLA-identical sibling donor at a single center using mobilized PBSCs.
The aim of the study was to analyze the incidence of the major life-threatening infections, the IRM and the NRM over a 15-year time period, identifying their risk factors, as well as analyzing the impact of the major specific severe infections on the IRM and the NRM.
Patients and methods

Patient selection
Data on all consecutive adult patient who received a first allogeneic PBSCT (alloPBSCT) at the Hospital de la Santa Creu i Sant Pau, Barcelona, were retrieved from the institutional database, containing details on underlying disease, transplantation procedure and outcome. Patients were transplanted from November 1993 to December 2008, and the follow-up of surviving patients was updated as 30 August 2009, with at least 9 months follow-up at the time of analysis. A detailed case report form on the supportive care given and the severe infections observed was retrospectively completed for each patient included in the study.
Definitions
Disease status at transplant was categorized as early (acute leukemia or poor-risk myelodysplasia in first CR, untreated good-risk myelodysplasia, first chronic-phase CML, lymphoid malignancy in first remission), or non-early status (acute leukemia or myelodysplasia in second or higher CR or in refractory or relapsed phase, CML in second chronic phase or accelerated-phase, lymphoid malignancy in second or higher remission or in refractory or relapsed status), as well as patients having received a previous autologous HSCT. Assessment, grading and treatment of acute GVHD (aGVHD) and chronic GVHD were performed using standard methods. 4, 5 Conditioning regimens were divided into conventional high-dose regimens (CONV) or reduced-intensity conditioning (RIC) regimens. CONV included high-dose TBI (total dose 13.5 Gy) plus CY (120 mg/kg) or BU (16 mg/kg, orally with pharmacokinetic dose adjustment) plus CY (120 mg/kg). RIC included fludarabine (150 mg/m 2 i.v. or equivalent oral dose) plus either oral BU (10 mg/kg, orally with pharmacokinetic dose adjustment) or melphalan (70-140 mg/m 2 ) in myeloid and lymphoid malignancies, respectively. 6 In addition, PBSCs were either infused to the patient without ex vivo manipulation (unmanipulated (UM)) or were infused after CD34 þ -cell selection. 7 Thus, three major types of alloPBSCT were performed during the study period: (1) CONV-UM); (2) CONV-CD34 þ ; and (3) RIC-UM.
A severe or life-threatening/fatal infection was defined according to the Blood and Marrow Transplant Clinical Trials Network criteria (https://web.emmes.com/study/bmt2/ public/Definition/Definitions_of_Inf_Severity.pdf). Specific severe infectious complications were defined according to accepted definitions, as included in the guidelines for defining infections in HSCT recipients of the Infectious Diseases Working Party of the European Group for Blood and Marrow Transplantation (available upon request at www. ebmt.org), which can be summarized as follows: (1) A severe bacterial infection was defined as any bacterial organ infection and/or bacteremia by any bacterial organism in a febrile patient, except for coagulase-negative staphylococci, Micrococcus spp. and saprophytic Corynebacterium spp., which were not included in the present analysis as they very rarely, if ever, lead to death. In patients with fever and bacteremia septic shock was defined by at least two of the following three criteria: systolic blood pressure o90 mm Hg (in a previously normotensive patient), heart rate 4120 per minute and respiratory rate 428 per minute. We analyzed in detail all bacterial infections that occurred in the first 100 days post transplant and later infections that led to the patient's death; (2) invasive fungal infections were divided into candidemia, invasive aspergillosis and other mycoses. The level of certainty of invasive aspergillosis was re-defined according to the 2008 update of the EORTC-MSG criteria as probable (clinical signs and symptoms, compatible X-ray findings plus a positive respiratory tract culture for Aspergillus spp. or two or more serum galactomannan indexes X0.5) and definite (positive histology for an invasive mold infection by Aspergillus) aspergillosis; (3) CMV infection was defined as the presence of a single pp65 Ag-positive leukocyte or a positive viremia in peripheral blood or two consecutive blood samples with a quantitative PCR for CMV X1000 copies/mL, as well as documentation of CMV disease without previous positive antigenemia or PCR. CMV disease was defined as the demonstration of CMV in biopsy or autopsy specimens from clinically involved visceral sites by culture and/or histology or whether CMV was detected in culture (CONV or shell-vial) of BAL samples in the presence of new or changing pulmonary infiltrates; (4) nonlocalized or disseminated VZV infection was defined as involvement of two or more skin dermatomes or visceral involvement; (5) pneumonia by HSV or respiratory viruses was defined as any new radiological lung infiltrate in a febrile patient with respiratory symptoms with the identification of the specific virus in samples obtained from the lower respiratory tract or lung tissue; (6) other less common infections, such as toxoplasmosis disease or progressive multifocal leukoencephalopathy, were defined by established definitions.
Patients were considered to have died from infection (that is, IRM) if death was attributable to a recent severe infection and/or an infection was identified at autopsy.
Outcomes
The primary outcome that was analyzed for risk factors by univariate and multivariate analysis in our study was the 2-year IRM. The risk factors for NRM were also analyzed as a secondary objective. Other secondary objectives were the comparison of the frequencies or incidences of the specific severe infections between time periods.
Statistical analysis
The infection data were collected retrospectively by at least two physicians (RM and AK, DV, JLP or another co-author) until the patient's death or last follow-up. However, data were analyzed up to 2 years post transplant, to assure an equivalent follow-up in most cases and as most severe infections occur during this time period after alloPBSCT. 3, 8 The w 2 -statistic or Fisher's exact test was used to establish differences in the distribution of discontinuous variables, whereas Student's t-test or Mann-Whitney's U-test was applied to compare continuous variables. All reported P-values are two sided, and a significance level of 0.05 was used. OS was calculated using the Kaplan-Meier estimate, with univariate comparisons carried out using the log-rank test.
Patients who died with an active life-threatening infection were categorized as an IRM. The incidences of IRM, NRM, aGVHD grades II-IV, chronic GVHD, disease progression and the incidence of the major infectious events Infections after allogeneic PBSCTstudied were calculated from the time of transplantation using cumulative incidence estimates. Progression of the underlying malignancy and NRM from another cause were competing events for IRM, disease progression was the competing event for NRM, and NRM was the competing event for progression. Disease progression and NRM from other causes were competing events for GVHD and the infectious events analyzed. Patients who were still alive and progression-free at the time of analysis were censored at the last follow-up or at 2 years post transplant.
Univariate analysis of the variables that influenced IRM, NRM and infectious events were performed using proportional hazards models for competing risks (Gray's test). The variables that showed at least a trend in univariate analysis (Po0.1) and those that were relevant in previous studies were used in a multivariate Cox proportional hazards regression analysis, checking for the assumption of proportional hazards over time for each tested variable. Variables or events that occur post transplant were analyzed as possible risk factors for IRM and NRM in the framework of Cox models as time-dependent covariates (occurrence of aGVHD grades II-IV, bacterial infections, development on an invasive fungal infection (IFI), CMV disease and pneumonia by a respiratory virus or by a herpes virus), switching from absent (0) to present (1) at the moment of occurrence of each covariate/event. To test whether the effect of the time period (described below) could depend on another risk factor, an interaction with that risk factor was added and tested for significance with the usual likelihood ratio test. The statistical analyses were performed using SPSS version 18.0 (SPSS, Chicago, IL, USA), with the exception of the cumulative incidence plots, which were carried out with NCSS 2004 (Number Cruncher Statistical System, Kaysville, UT, USA) and the univariate Gray's test, which was carried out using the Cmprsk package R software (The R Foundation, Vienna, Austria).
To illustrate the effect of grade II-IV aGVHD on the subsequent event IRM (Figure 1 ), we constructed landmark plots of the cumulative incidence of IRM. For patients who developed grade II-IV aGVHD in each time period, the cumulative incidence of IRM was plotted as a function of time as onset of aGVHD, and not from the day of transplant. In a similar manner, to plot the effect of developing an IFI or CMV disease on the subsequent event NRM (Figures 2a and b, respectively) , we constructed landmark plots of the incidence of NRM, but starting at the time of onset of an IFI or CMV disease, respectively. The corresponding landmark cumulative incidence plots for the 1994-2000 and 2001-2008 time periods were compared by univariate analysis as previously described.
Separation by time periods
An initial analysis of 2-year OS, IRM and NRM showed that there were significant changes over time, with a progressive increase in OS and a reduction of the IRM and NRM. In an effort of establishing an optimal time point to be used as a cutoff for different time periods, we analyzed the major changes in the alloPBSCT protocols and supportive care used in our center from 1994 to 2008. As shown in Table 1 , major changes occurred during the 1999-2000 time interval. In summary, since mid-1999, patients considered at high risk for NRM (age above 50 years, before autologous HSCT and cardiac, pulmonary, metabolic, renal or other comorbidities that precluded a CONV high-dose conditioning regimen) were included in a RIC regimen, with a flexible upper age limit of 70 years. Until 1999, patients above 45 years of age (upper age limit 60 years) with no comorbidities received a CONV CD34 þ -selected PBSCT; patients with leukemia in an early disease status also received a CD34 þ -selected PBSCT during the entire study period, but since 2000 only up to the age of 50 years. GVHD prophylaxis consisted in CyA combined with steroids in most recipients of a CONV-CD34 þ -selected PBSCT until 1999-2000; some recipients of a CONV-UM PBSCT also received CyA plus steroids during this time period as part of a clinical trial. In the year 2000, however, two concomitant changes were introduced: CyA plus steroids was abandoned as GHVD prophylaxis and CyA in monotherapy was used as GVHD prophylaxis in CONV-CD34 þ -selected PBSCT recipients. Second, the dose of CD34 þ cells and CD3 þ cells infused was targeted; in CD34 þ -selected PBSCT the final dose of CD34 þ cells infused was adjusted to 2-4 Â 10 6 /kg and the dose of CD3 þ cells was adjusted to 3 Â 10 5 /kg, 9 whereas in unmanipulated PBSCT (both CONV and RIC protocols) the dose of CD34 þ cells ranged from 4 to 8 Â 10 6 /kg, with the accompanying unadjusted CD3 þ cells. Other changes in supportive care are shown in Table 1 . Of course, all changes did not occur at the same exact time point, but as major changes occurred during the 1999-2000 interval, we separated the study population into two time periods according to the date of transplantation: an earlier 1994-2000 group and a later 2001-2008 group. The impact of time on all outcomes analyzed was thus expressed through this simplified binary variable.
Results
During the 15-year study period, 580 consecutive patients 415 years of age received an alloPBSCT from an HLAidentical sibling at our institution and were included in this study.
Patients and transplantation procedures
As a result of the changes in alloHSCT protocols (summarized in part in Table 1 ), patient characteristics differed between both study periods, as shown in detail in Table 2 . Major differences include younger median patient age in the 1994-2000 period, higher proportion of patients with acute leukemia and myeloid malignancies, lower proportion of non-early disease status, lower proportion of patients with poor ECOG performance status at transplant, few RIC transplants and larger proportion of GVHD prophylaxis with CyA plus steroids during this 1994-2000 period. The median follow-up for patients alive was 57 months in the 1994-2000 cohort vs 44 months in the 2000-2008 group.
GVHD and transplant outcomes
As shown in Table 3 , the incidence of grade II-IV and grade III-IV aGVHD did not differ along the 15-year study period (for grade II-IV, 28% in the 1994-2000 vs 26% in the 2001-2008 period). On day þ 120, a similar proportion of patients were alive in both groups and thus evaluable for chronic GVHD. The incidence of chronic GVHD was lower in the 1994-2000 period (40 vs 56%, P ¼ 0.02), an expected finding due to the higher proportion of T-celldepleted (CONV-CD34 þ ) PBSCT during this period (49 vs 16%). However, the proportion of patients who received high-dose steroids post transplant (dose of prednisone or equivalent X1 mg/kg during 2 or more weeks) was higher in the 1994-2000 period (71 vs 44%, Po0.001) as 47% of these patients received steroids as part of the GVHD prophylaxis regimen.
The 2-year OS, relapse incidence, NRM and IRM for each type of alloPBSCT (CONV-UM, CONV-CD34 þ and RIC-UM) and separated by time periods are shown in detail in Table 3 . The relapse incidence remained Table 3 ). Similar findings were observed in the 2-year IRM, which decreased from 22 to 11% from the 1994-2000 to the 2001-2008 time periods (Po0.001). Figure 3 shows the 2-year incidence of NRM and IRM in each time period. In the CONV-UM and CONV-CD34 þ transplant groups, the IRM decreased from 19 to 6% (P ¼ 0.05) and 26 to 7% (P ¼ 0.04), respectively.
Severe infections
Early bacterial infections. Fever during the neutropenic (early post transplant) period occurred more commonly in the 1994-2000 period (94 vs 72%). During the first 100 days after transplant, invasive bacterial infections occurred in 21% of patients in both time periods, as shown in Table 4 . However, septic shock occurred in 12 patients (4%) in the 1994-2000 group and none in the 2001-2008 period (Po0.01). As the use of steroids as GVHD prophylaxis was unevenly distributed between the two time periods and these may predispose to bacterial infections, we analyzed the probability of septic shock in the 1994-2000 period according to the use or not of steroids as prophylaxis; septic shock was linked to steroid prophylaxis, as 11/148 (7%) of these patients developed this complication in contrast to 1/167 (1%) who received non-steroid-containing GVHD prophylaxis (Po0.05). A large number of bacterial species were isolated, with only one identifiable difference between time periods (see Table 4 for details); bacteremia by viridans group streptococci was more common in the 1994-2000 period (7 vs 3%, P ¼ 0.04). CMV and other viral infections. developed CMV disease, although they were negative in the previous screening tests (pp65 Ag in all 15 cases), suggesting that the CMV infection screening strategy was more sensitive in the latter period.
The overall incidence and characteristics of other lifethreatening viral infections are shown in Table 4 . The rate of disseminated VZV infection was higher in the 1994-2000 period (8 vs 3%, P ¼ 0.04), whereas pneumonia due to respiratory viruses was diagnosed more often in the 2001-2008 period, but these viruses were studied systematically in BAL and lung samples by sensitive methods since 1998, and thus the different rates along the years cannot be compared. 10 One patient from each time period died from progressive multifocal leukoencephalopathy. Table 5 shows the causes of 2-year IRM during both study periods. The cumulative incidence of IRM was 22% in the 1994-2000 period and 11% in the 2001-2008 period (Po0.01). The only differences in the specific causes of IRM was a higher proportion of deaths due to IFI during the 1994-2000 period (6.3 vs 3.5% of patients, P ¼ 0.02), and the higher rate of clinically documented infections without microbiological documentation in the same time period (9.5 vs 2%, respectively). There was a remarkable delay in the median times to the onset of lethal bacterial, fungal and CMV disease during the 2001-2008 period, as shown in detail in Table 5 .
IRM
Results of the univariate and multivariate Cox regression analyses of IRM are shown in Table 6 . For the entire 15-year period, multivariate analysis identified five variables associated with a higher risk of IRM: (i) time period (hazard ratio (HR) 3.9 (95% confidence interval (CI) 1. Table 6 , the four variables identified in the analysis of the entire 15-year period were also found to be statistically significant in the analysis of the two time periods (performance status, grade II-IV aGVHD, IFI and CMV disease). In addition, two additional variables were identified in each time period; during the 1994-2000 period: (i) non-early disease status (P ¼ 0.019); and (ii) steroids as part of GVHD prophylaxis (P ¼ 0.04); and during the 2001-2008 period: (i) patient age 460 years (P ¼ 0.04); and (ii) very high hematopoietic cell transplantation comorbidity index (45 points, according to Sorror et al. 11 (P ¼ 0.01). This latter variable was not available for most patients transplanted in the 1994-2000 period.
Three subgroup multivariate analyses restricted to (i) patients with acute leukemia and myelodysplastic syndrome (n ¼ 311), (ii) GVHD prophylaxis with CyA plus MTX (n ¼ 321) and (iii) recipients of CONV conditioning regimens (n ¼ 385) were performed. In all three analyses, time period was found to have a similar impact on IRM (Po0.05 in all three subgroup Cox models) (details not shown). These results suggest that improvements in IRM during the 2001-2008 period were not solely related to changes in the underlying diseases, changes in GVHD prophylaxis or introduction of RIC regimens.
To analyze the change over time in the IRM in different transplant risk categories, we calculated each patient's risk score according to the recently published EBMT scoring system, 15 which is based on patient age, disease stage, time interval from diagnosis to transplant, donor type and donor-recipient sex combination. The 2-year incidence of Table 7 shows the univariate and multivariate analysis of risk factors for NRM for the entire 15-year study period. Three separate subgroup multivariate analyses on the risk factors for 2-year NRM were performed, which were restricted to (i) patients with acute leukemia and myelodysplastic syndrome (n ¼ 311), (ii) GVHD prophylaxis with CyA plus MTX (n ¼ 321) and (iii) recipients of CONV conditioning regimens (n ¼ 385). As occurred with IRM, in all three subgroup analyses the time period was found to have a similar impact on NRM (Po0.05 in all three subgroup Cox models)(details not shown). Hence, these results also suggest that improvements in the 2-year NRM from the 1994-2000 to the 2001-2008 period were not solely related to changes in the underlying diseases, discontinuation of steroids for GVHD prophylaxis or introduction of RIC regimens.
NRM
A separate analysis was carried out to study the change over time in the NRM in different EBMT risk categories. 15 The 2-year incidence of NRM in the 1994-2000 and Table 4 Documented severe infections by time period (% in parentheses) (5) 4 (1) 25 ( 
The bacterial species implicated in cases of septic shock were viridans group streptococci (n ¼ 5), E. coli (n ¼ 3), P. aeruginosa (n ¼ 1), S. maltophilia (n ¼ 1), P. mirabilis (n ¼ 1), K. pneumoniae (n ¼ 1) and Acinetobacter sp. (n ¼ 1). c Univariate comparison of cumulative incidence. Other P-values refer to comparison of rates (see Statistical Analysis). d Patient or donor positive for CMV IgG. e The respiratory viruses implicated were respiratory syncitial virus (n ¼ 7), influenza A (n ¼ 8), metapneumovirus (n ¼ 5), adenovirus (n ¼ 4), parainfluenza type 3 (n ¼ 3) and rhinovirus (n ¼ 2).
Table 6
Summary of the results of multivariate analyses for 2-year infection-related mortality by the time period 
Discussion
Over the past two decades, numerous changes have been introduced in the transplantation procedure and the supportive care after an alloHSCT. However, 2-year NRM still exceeds 20% in unselected recipients of an HLA-identical sibling transplant, and opportunistic infections (with or without GVHD) are implicated in more than half of these deaths. 3, 8, 12 Multicenter and registry studies show that NRM may decrease over time, 2, 3, [13] [14] [15] [16] but no such data are available for IRM. These analyses cannot define the specific reasons for these changes, nor can they easily segregate the relative impact of each participating center in the overall findings.
The study of large series of a specific type of alloHSCT from single institutions may offer relevant information on the changes in NRM and IRM over time, as well as the changes in the major life-threatening opportunistic infections and their impact on mortality. Several observations on the specific severe infections diagnosed merit some discussion. The reduction in the rates of early post transplant infections, such as febrile neutropenia, viridans group streptococcal bacteremia, bacterial septic shock and invasive candidiasis, may be related to the introduction of RIC regimens that cause less mucosal barrier injury. 12, 17, 18 In addition, the rates of CMV infection and pneumonia by respiratory viruses between study periods are not comparable as more sensitive diagnostic tests were used during the latter period.
On the other hand, we found no major differences in the rates of invasive aspergillosis and CMV disease, which still represent major threats to recipients of an alloHSCT worldwide. An interesting observation is the marked reduction of patients who developed CMV disease without having any previous positive blood screening tests (15 cases vs 0 cases in the 1994-2000 vs 2001-2008 period). As the median number of screening tests performed during the first 6 months post transplant did not differ (1.2 per week vs 1.1 per week, respectively), this reduction may be attributed to the lower sensitivity of the screening test used in the 1994-2000 period (pp65 Ag test as opposed to the quantitative PCR test). Finally, the reduction in non-localized VZV infections and toxoplasmosis suggests a better compliance with long-term acyclovir and cotrimoxazole prophylaxis, respectively, in high-risk patients. 19, 20 Reduction in the 2-year incidence of IRM from 22% in the initial to 11% in the latter period is a positive finding from this study. The introduction of RIC regimens was not responsible for this reduction, as there was a marked decrease in the 2-year incidence of IRM in CONV alloPBSCT from the 1994-2000 to the 2001-2008 period, as shown in Table 3 . In addition, the multivariate analyses failed to show a correlation of IRM and NRM with intensity of the conditioning regimen, a topic of intense debate, 12, 21, 22 which could be solved only by having similar patients in each transplant group. However, our guidelines specifically directed patients with a higher risk of NRM to a RIC protocol, and the lack of its impact on NRM (and IRM) should be considered as a positive finding.
The rate of death from specific infections was similar for all pathogens, except IFI, which decreased from 6.3 to 3.5% (P ¼ 0.04) of patients over time. In addition, the mortality rate from clinically documented infections without microbiological documentation decreased from 9.5 to 2% (P ¼ 0.01) of patients transplanted. This difference supports the improvement in the ability to diagnose patients with a severe infectious syndrome during the 15-year interval. A relevant observation was the significant delay in the median day of onset of lethal opportunistic infections (Table 5) ; bacterial, fungal and viral infections which led to the patients' death occurred at a median of more than 4 months after transplantation in the 2001-2008 period, while they occurred much earlier after transplant in the 1994-2000 period.
Multivariate analysis of the risk factors for IRM and NRM showed that the time period had a strong impact on both outcomes. In addition, three post transplant events (analyzed as time-dependent covariates) also had an independent impact on IRM and NRM: grade II-IV aGVHD, development of an IFI and development of CMV disease. Figure 1 shows the landmark incidence of IRM in patients with aGVHD during both study periods. Despite the fact that GVHD and its treatment is a wellknown risk factor for severe opportunistic infections, the reduction of IRM in these patients from 49 to 32% over time highlights the positive impact of the time period on this outcome. To graphically estimate the impact of IFI and CMV disease on the 2-year NRM, we calculated its incidence in patients with both types of infections also using a landmark approach (see Statistical Analysis); Figures 2a and b show that although the 2-year NRM in patients with IFI and CMV disease, respectively, is very high, improvements are apparent in both types of infection from the 1994-2000 to the 2001-2008 period.
The hematopoietic SCT-comorbidity index was developed as a simple tool for estimating the risk of NRM (and OS) based on the number and severity of comorbidities found in a specific patient before alloHSCT. 11 Although several independent studies have validated the hematopoietic SCT-comorbidity index for predicting NRM, this study is the first to show its validity in predicting the risk of IRM. As the full hematopoietic SCT-comorbidity index was available only for patients in the 2001-2008 time period, we were able to verify its impact only in the separate multivariate analyses carried out for each time period (Table 6) .
It is comforting to see that IRM and NRM did not increase despite an increase in patient age, poor performance status and non-early disease status over the same time period. Unfortunately, the retrospective nature of this study and the logical differences in patient and transplantrelated variables between the two time periods do not allow the identification of the exact reasons for the reduction in IRM and NRM with time. However, it is tempting to link these improvements with some key changes in our transplantation procedures. In fact, the two time cohorts studied roughly correspond to two different period in our alloPBSCT program, with three major components: (i) incorporation of RIC protocols for patients at high risk for NRM since 1999; (ii) discontinuation of steroids for GVHD prophylaxis since 2000; and (iii) strict targeting of the CD34 þ cell dose infused in all cases (and adjusted dose of the CD3 þ cell dose infused in CONV-CD34 þ selection). Prophylaxis with steroids was discontinued after a multicenter local study suggested that they increased the IRM and NRM, and the current results confirm that observation. 8, 23 The dose of the CD34 þ cells infused was targeted to 4 to 8 Â 10 6 /kg, based on studies from our group and others, which suggested that in UM-alloPBSCT a high dose (44 Â 10 6 /kg) of CD34 þ cells infused reduced NRM and improved survival, 24 ,25 but a very high dose (48 Â 10 6 / kg) can be detrimental on these outcomes. 4, [26] [27] [28] On the other hand, retrospective studies from our collaborative group showed different results in CD34 þ cell-selected CONV PBSCT; specifically, the optimal dose of CD34 þ cells and CD3 þ cells infused to avoid graft rejection and improve NRM were estimated to range from 2 to 4 Â 10 6 /kg to 3 Â 10 5 /kg, respectively. 9, 25 Undoubtedly, advances in the methods for the diagnosis of opportunistic infections and their treatment also contribute to these improvements, 1 and the multifaceted improvement in care through experience of the multidisciplinary teams also contribute to these changes over time. On the other hand, failure to improve in relapserelated mortality, the incidence of grade III-IV aGVHD and NRM from non-infectious causes highlights the challenges we must still face if we are to continue to significantly improve the survival. A similar conclusion was reached by Bacigalupo et al. 13 in their single-center study, which included several types of alloHSCT from 1976 to 2002.
In summary, the 2-year IRM and NRM have significantly improved over a 15-year period, which can be partially attributed to specific changes in transplant procedures and supportive care. aGVHD, fungal infections and CMV disease have an independent impact on both IRM and NRM. Further reductions of these outcomes will require reduction of severe GVHD while maintaining antimicrobial immune mechanisms.
